Questionnaire Survey on Dupilumab or Mepolizumab in patients with severe allergic diseaes : The Significance of Self-Injection

Questionnaire Survey on Dupilumab or Mepolizumab in patients with severe allergic diseaes : The Significance of Self-Injection - Questionnaire Survey on Dupilumab or Mepolizumab in patients with severe allergic diseaes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049878

Enrollment

Registered

2022-12-23

Start date

2021-05-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Atopic dermatitis, Chronic sinusitis with nasal polyps

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with asthma, atopic dermatitis, or chronic sinusitis with nasal polyps requiring biologics

Exclusion criteria

Exclusion criteria: Subjects who do not consent to the survey

Design outcomes

Primary

Measure	Time frame
Usefulness, Safety, and Medical Economics (Self-payment) of Self-Injection	—

Countries

Japan

Contacts

Public ContactMasato Muraki

Kindai University Nara Hospital Department of Respiratory Medicine and Allergology

muraki-m@med.kindai.ac.jp0743-77-0880

Outcome results